{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:12:09Z","timestamp":1781521929960,"version":"3.54.1"},"reference-count":310,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Institute of Health","award":["1R21AI193648"],"award-info":[{"award-number":["1R21AI193648"]}]},{"name":"the National Institute of Health","award":["1R01EB038005"],"award-info":[{"award-number":["1R01EB038005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The Orthoflavivirus genus belongs to the Flaviviridae family. Orthoflaviviruses include major clinically relevant arthropod-borne human viruses such as Dengue, Zika, yellow fever, West Nile and tick-borne encephalitis virus. These viruses pose an increasing threat to global health due to the expansion of arthropod habitats, urbanization, and climate change. While vaccines have been developed for certain orthoflaviviruses with varying levels of success, critical challenges remain in achieving broadly deployable vaccines that combine a robust safety profile with durable immunity against many current and emerging orthoflaviviruses. This review provides a snapshot of established and emerging vaccine platforms against orthoflaviviruses, with a particular emphasis on those leveraging the envelope glycoprotein E as the primary antigen. We examine the strengths and disadvantages of these different platforms in eliciting safe, durable, and robust orthoflavivirus immunity, and discuss how specific attributes such as multivalency, authentic epitope presentations, and logistical practicality can enhance their value in preventing orthoflavivirus infection and disease.<\/jats:p>","DOI":"10.3390\/vaccines13101015","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:49:34Z","timestamp":1759142974000},"page":"1015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-6945","authenticated-orcid":false,"given":"Giulia","family":"Unali","sequence":"first","affiliation":[{"name":"Department of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA"},{"name":"National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-6767","authenticated-orcid":false,"given":"Florian","family":"Douam","sequence":"additional","affiliation":[{"name":"Department of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA"},{"name":"National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1097\/MS9.0000000000001313","article-title":"Upsurge of Powassan virus disease in northeastern United States: A public health concern-a short communication","volume":"85","author":"Anis","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pustijanac, E., Bursic, M., Talapko, J., Skrlec, I., Mestrovic, T., and Lisnjic, D. (2023). Tick-Borne Encephalitis Virus: A Comprehensive Review of Transmission, Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Prevention. Microorganisms, 11.","DOI":"10.3390\/microorganisms11071634"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JS9.0000000000000207","article-title":"Usutu virus: A Flavivirus on the rise amid COVID-19 and monkeypox","volume":"109","author":"Gupta","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/cid\/ciac794","article-title":"Japanese Encephalitis Emergence in Australia: The Potential Population at Risk","volume":"76","author":"Yakob","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.ento.54.110807.090510","article-title":"Ecology and geographical expansion of Japanese encephalitis virus","volume":"54","author":"Ritchie","year":"2009","journal-title":"Annu. Rev. Entomol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13567-025-01460-9","article-title":"Usutu virus continues to spread across Europe: First report of multiple molecular detections of the USUV Africa 2 and Africa 3 lineages in free-living and captive birds in Poland, July\u2013November 2023","volume":"56","author":"Dziadek","year":"2025","journal-title":"Vet. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1038\/s41467-025-63122-w","article-title":"One Health approach uncovers emergence and dynamics of Usutu and West Nile viruses in the Netherlands","volume":"16","author":"Munger","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Schilling, M., Lawson, B., Spiro, S., Jagdev, M., Vaux, A.G.C., Bruce, R.C., Johnston, C.J., Abbott, A.J., Wrigglesworth, E., and Pearce-Kelly, P. (2025). Vertical transmission in field-caught mosquitoes identifies a mechanism for the establishment of Usutu virus in a temperate country. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-09335-x"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(08)60238-X","article-title":"Pathogenic flaviviruses","volume":"371","author":"Gould","year":"2008","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ryan, S.J., Carlson, C.J., Mordecai, E.A., and Johnson, L.R. (2019). Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007213"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1038\/s41467-023-43954-0","article-title":"Interactions between climate change, urban infrastructure and mobility are driving dengue emergence in Vietnam","volume":"14","author":"Gibb","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115700","DOI":"10.1016\/j.celrep.2025.115700","article-title":"Future threats: Animal orthoflaviviruses that currently infect fewer than 100 people per year","volume":"44","author":"Gendler","year":"2025","journal-title":"Cell Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMc1610613","article-title":"Fatal Zika Virus Infection with Secondary Nonsexual Transmission","volume":"375","author":"Swaminathan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(16)00502-X","article-title":"Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection","volume":"387","author":"Karimi","year":"2016","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1080\/21505594.2021.1996059","article-title":"Pathogenesis and virulence of flavivirus infections","volume":"12","author":"Heunis","year":"2021","journal-title":"Virulence"},{"key":"ref_17","first-page":"8630349","article-title":"Powassan Encephalitis: A Case Report from New York, USA","volume":"2022","author":"Bazer","year":"2022","journal-title":"Case Rep. Neurol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.humpath.2014.01.022","article-title":"Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar","volume":"45","author":"Aye","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/341410","article-title":"Coagulation abnormalities in dengue hemorrhagic Fever: Serial investigations in 167 Vietnamese children with Dengue shock syndrome","volume":"35","author":"Wills","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rodrigo, C., Sigera, C., Fernando, D., and Rajapakse, S. (2021). Plasma leakage in dengue: A systematic review of prospective observational studies. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06793-2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e17419","DOI":"10.1016\/j.heliyon.2023.e17419","article-title":"Secondary dengue serotype 1 infection causing dengue shock syndrome with rhombencephalitis and bleeding associated with refractory thrombocytopenia: A case report","volume":"9","author":"Surabotsophon","year":"2023","journal-title":"Heliyon"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3201\/eid1107.040991","article-title":"West Nile virus-associated flaccid paralysis","volume":"11","author":"Sejvar","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_23","unstructured":"Centers for Disease Control and Prevention (CDC) (2002). Acute flaccid paralysis syndrome associated with West Nile virus infection\u2014Mississippi and Louisiana, July\u2013August 2002. MMWR Morb. Mortal. Wkly. Rep., 51, 825\u2013828."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hart, J., Tillman, G., Kraut, M.A., Chiang, H.S., Strain, J.F., Li, Y., Agrawal, A.G., Jester, P., Gnann, J.W., and Whitley, R.J. (2014). West Nile virus neuroinvasive disease: Neurological manifestations and prospective longitudinal outcomes. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-248"},{"key":"ref_25","first-page":"e70107","article-title":"Acute Flaccid Myelitis Caused by West Nile Virus: A Case Report and Neuroimaging Correlate","volume":"16","author":"Creswell","year":"2024","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"taz043","DOI":"10.1093\/jtm\/taz043","article-title":"Managing severe yellow fever in the intensive care: Lessons learnt from Brazil","volume":"26","author":"Kallas","year":"2019","journal-title":"J. Travel Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijid.2020.01.039","article-title":"Clinical profiles and factors associated with mortality in adults with yellow fever admitted to an intensive care unit in Minas Gerais, Brazil","volume":"93","author":"Barbosa","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4269\/ajtmh.18-0882","article-title":"Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, Sao Paulo, Brazil, 2018","volume":"101","author":"Ribeiro","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(19)30125-2","article-title":"Predictors of mortality in patients with yellow fever: An observational cohort study","volume":"19","author":"Kallas","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/brain\/awf116","article-title":"Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis","volume":"125","author":"Solomon","year":"2002","journal-title":"Brain"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Van Tan, L., Qui, P.T., Ha, D.Q., Hue, N.B., Bao, L.Q., Van Cam, B., Khanh, T.H., Hien, T.T., Chau, N.V.V., and Tram, T.T. (2010). Viral etiology of encephalitis in children in southern Vietnam: Results of a one-year prospective descriptive study. PLoS Neglected Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000854"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e51027","DOI":"10.7554\/eLife.51027","article-title":"Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000-2015","volume":"9","author":"Quan","year":"2020","journal-title":"eLife"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4269\/ajtmh.17-0054","article-title":"Clinical Characteristics of Severe Japanese Encephalitis: A Case Series from South Korea","volume":"97","author":"Sunwoo","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/archneur.60.12.1760","article-title":"A comparison of clinical and radiological findings in adults and children with Japanese encephalitis","volume":"60","author":"Kalita","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(01)00589-5","article-title":"Seizures in Japanese encephalitis","volume":"190","author":"Misra","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika Virus Infection in Pregnant Women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1473-3099(16)00095-5","article-title":"Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: A case study","volume":"16","author":"Calvet","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejogrb.2021.07.012","article-title":"Zika virus infection in pregnant women and their children: A review","volume":"265","author":"Gonce","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Souza, J.P., Meio, M., de Andrade, L.M., Figueiredo, M.R., Gomes Junior, S.C., Pereira Junior, J.P., Brickley, E., and Lopes Moreira, M.E. (2021). Adverse fetal and neonatal outcomes in pregnancies with confirmed Zika Virus infection in Rio de Janeiro, Brazil: A cohort study. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0008893"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Grant, R., Flechelles, O., Tressieres, B., Dialo, M., Elenga, N., Mediamolle, N., Mallard, A., Hebert, J.C., Lachaume, N., and Couchy, E. (2021). In utero Zika virus exposure and neurodevelopment at 24 months in toddlers normocephalic at birth: A cohort study. BMC Med., 19.","DOI":"10.1186\/s12916-020-01888-0"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa1709481","article-title":"Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas","volume":"378","author":"Hoen","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"k4431","DOI":"10.1136\/bmj.k4431","article-title":"Maternal-fetal transmission and adverse perinatal outcomes in pregnant women infected with Zika virus: Prospective cohort study in French Guiana","volume":"363","author":"Pomar","year":"2018","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e200047","DOI":"10.1212\/NXI.0000000000200047","article-title":"Guillain-Barre Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies","volume":"10","author":"Davies","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1941874419844888","article-title":"An Overview of Powassan Virus Disease","volume":"9","author":"Khan","year":"2019","journal-title":"Neurohospitalist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1080\/22221751.2022.2086070","article-title":"Comparison of laboratory and immune characteristics of the initial and second phase of tick-borne encephalitis","volume":"11","author":"Bogovic","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bogovic, P., Logar, M., Avsic-Zupanc, T., Strle, F., and Lotric-Furlan, S. (2014). Quantitative evaluation of the severity of acute illness in adult patients with tick-borne encephalitis. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/841027"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1438-4221(02)80012-1","article-title":"Tick-borne encephalitis (TBE) in Germany and clinical course of the disease","volume":"291","author":"Kaiser","year":"2002","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ1005","article-title":"Emerging Cases of Powassan Virus Encephalitis in New England: Clinical Presentation, Imaging, and Review of the Literature","volume":"62","author":"Piantadosi","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/cid\/ciad454","article-title":"Powassan Virus Encephalitis: A Tertiary Center Experience","volume":"78","author":"Mendoza","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","first-page":"e71780","article-title":"Neurological Complications Associated With the Powassan Virus and Treatment Interventions","volume":"16","author":"Ndukwe","year":"2024","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1469-0691.2004.01022.x","article-title":"Tick-borne virus diseases of human interest in Europe","volume":"10","author":"Charrel","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_52","first-page":"25","article-title":"A case series of fatal meningoencephalitis in Mongolia: Epidemiological and molecular characteristics of tick-borne encephalitis virus","volume":"10","author":"Baasandavga","year":"2019","journal-title":"West. Pac. Surveill. Response J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3201\/eid2807.220010","article-title":"Deaths from Tick-Borne Encephalitis, Sweden","volume":"28","author":"Varnaite","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0056024","DOI":"10.1128\/jvi.00560-24","article-title":"Age-dependent Powassan virus lethality is linked to glial cell activation and divergent neuroinflammatory cytokine responses in a murine model","volume":"98","author":"Mladinich","year":"2024","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00106-17","DOI":"10.1128\/CMR.00106-17","article-title":"Tick-Borne Flaviviruses, with a Focus on Powassan Virus","volume":"32","author":"Kemenesi","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"taaa138","DOI":"10.1093\/jtm\/taaa138","article-title":"Safety of yellow fever vaccination in pregnancy: Findings from a cohort of active duty US military women","volume":"27","author":"Hall","year":"2020","journal-title":"J. Travel. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Roukens, A.H., Soonawala, D., Joosten, S.A., de Visser, A.W., Jiang, X., Dirksen, K., de Gruijter, M., van Dissel, J.T., Bredenbeek, P.J., and Visser, L.G. (2011). Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027753"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1016\/j.vaccine.2020.05.023","article-title":"Japanese encephalitis vaccination in pregnancy among U.S. active duty military women","volume":"38","author":"Khodr","year":"2020","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/nyas.13950","article-title":"Impact of recent and future climate change on vector-borne diseases","volume":"1436","author":"Caminade","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1111\/gcb.12534","article-title":"A continental risk assessment of West Nile virus under climate change","volume":"20","author":"Harrigan","year":"2014","journal-title":"Glob. Change Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ebiom.2016.03.046","article-title":"Climate Change and Aedes Vectors: 21st Century Projections for Dengue Transmission in Europe","volume":"7","author":"Quam","year":"2016","journal-title":"eBioMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1289\/EHP218","article-title":"An Analysis of the Potential Impact of Climate Change on Dengue Transmission in the Southeastern United States","volume":"125","author":"Butterworth","year":"2017","journal-title":"Environ. Health Perspect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e29820","DOI":"10.7554\/eLife.29820","article-title":"Epidemiological and ecological determinants of Zika virus transmission in an urban setting","volume":"6","author":"Lourenco","year":"2017","journal-title":"eLife"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41467-020-16010-4","article-title":"Accelerating invasion potential of disease vector Aedes aegypti under climate change","volume":"11","author":"Iwamura","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.ijid.2025.107940","article-title":"Global dengue epidemic worsens with record 14 million cases and 9000 deaths reported in 2024","volume":"158","author":"Haider","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"107192","DOI":"10.1016\/j.ijid.2024.107192","article-title":"Dengue outbreaks in Brazil and Latin America: The new and continuing challenges","volume":"147","author":"Sansone","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Moore, S.M. (2021). The current burden of Japanese encephalitis and the estimated impacts of vaccination: Combining estimates of the spatial distribution and transmission intensity of a zoonotic pathogen. PLoS Neglected Trop. Dis., 15.","DOI":"10.1101\/2021.04.08.21255086"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"taad029","DOI":"10.1093\/jtm\/taad029","article-title":"The evolving Japanese encephalitis situation in Australia and implications for travel medicine","volume":"30","author":"McGuinness","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2500401","DOI":"10.2807\/1560-7917.ES.2025.30.28.2500401","article-title":"Detection of West Nile virus via retrospective mosquito arbovirus surveillance, United Kingdom, 2025","volume":"30","author":"Bruce","year":"2025","journal-title":"Eurosurveillance"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.onehlt.2025.101041","article-title":"Patterns of West Nile virus vector co-occurrence and spatial overlap with human cases across Europe","volume":"20","author":"Taheri","year":"2025","journal-title":"One Health"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Laverdeur, J., Amory, H., Beckers, P., Desmecht, D., Francis, F., Garigliany, M.-M., Hayette, M.-P., Linden, A., and Darcis, G. (2025). West Nile and Usutu viruses: Current spreading and future threats in a warming northern Europe. Front. Virol., 5.","DOI":"10.3389\/fviro.2025.1544884"},{"key":"ref_74","first-page":"2200543","article-title":"Spatiotemporal spread of tick-borne encephalitis in the EU\/EEA, 2012 to 2020","volume":"28","author":"Beaute","year":"2023","journal-title":"Eurosurveillance"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12942-025-00388-9","article-title":"Different environmental factors predict the occurrence of tick-borne encephalitis virus (TBEV) and reveal new potential risk areas across Europe via geospatial models","volume":"24","author":"Kelly","year":"2025","journal-title":"Int. J. Health Geogr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"taae153","DOI":"10.1093\/jtm\/taae153","article-title":"Mapping the risk of tick-borne encephalitis in Europe for informed vaccination decisions","volume":"32","author":"Blanford","year":"2025","journal-title":"J. Travel. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102513","DOI":"10.1016\/j.ttbdis.2025.102513","article-title":"A new hotspot of tick-borne encephalitis virus (TBEV) in the Autonomous Province of Trento, Italy","volume":"16","author":"Ferrari","year":"2025","journal-title":"Ticks Tick Borne Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41564-019-0376-y","article-title":"Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus","volume":"4","author":"Kraemer","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Samy, A.M., Elaagip, A.H., Kenawy, M.A., Ayres, C.F., Peterson, A.T., and Soliman, D.E. (2016). Climate Change Influences on the Global Potential Distribution of the Mosquito Culex quinquefasciatus, Vector of West Nile Virus and Lymphatic Filariasis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163863"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Tonk-Rugen, M., Kratou, M., and Cabezas-Cruz, A. (2025). A Warming World, a Growing Threat: The Spread of Ticks and Emerging Tick-Borne Diseases. Pathogens, 14.","DOI":"10.3390\/pathogens14030213"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/v3020160","article-title":"Flavivirus cell entry and membrane fusion","volume":"3","author":"Smit","year":"2011","journal-title":"Viruses"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2010.09.005","article-title":"Molecular mechanisms involved in the early steps of flavivirus cell entry","volume":"13","author":"Kaufmann","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1128\/JVI.02210-06","article-title":"Rab 5 is required for the cellular entry of dengue and West Nile viruses","volume":"81","author":"Krishnan","year":"2007","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.virol.2018.03.009","article-title":"Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH","volume":"518","author":"Persaud","year":"2018","journal-title":"Virology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1128\/JVI.01840-06","article-title":"Antiviral peptides targeting the west nile virus envelope protein","volume":"81","author":"Bai","year":"2007","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11262-017-1508-1","article-title":"A synthetic peptide derived from domain III envelope glycoprotein of Dengue virus induces neutralizing antibody","volume":"54","author":"Mary","year":"2018","journal-title":"Virus Genes"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e01485-19","DOI":"10.1128\/mBio.01485-19","article-title":"Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies","volume":"10","author":"Gallichotte","year":"2019","journal-title":"mBio"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm0897-866","article-title":"Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate","volume":"3","author":"Chen","year":"1997","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbrc.2003.08.053","article-title":"Blocking the dengue virus 2 infections on BHK-21 cells with purified recombinant dengue virus 2 E protein expressed in Escherichia coli","volume":"309","author":"Chiu","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Dutta, S.K., and Langenburg, T. (2023). A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses, 15.","DOI":"10.3390\/v15040860"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e00104-20","DOI":"10.1128\/JVI.00104-20","article-title":"Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis","volume":"94","author":"Carbaugh","year":"2020","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1128\/JVI.79.13.8339-8347.2005","article-title":"Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains","volume":"79","author":"Beasley","year":"2005","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.celrep.2017.10.016","article-title":"Functional Analysis of Glycosylation of Zika Virus Envelope Protein","volume":"21","author":"Shan","year":"2017","journal-title":"Cell Rep."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Liang, J.J., Chou, M.W., and Lin, Y.L. (2018). DC-SIGN Binding Contributed by an Extra N-Linked Glycosylation on Japanese Encephalitis Virus Envelope Protein Reduces the Ability of Viral Brain Invasion. Front. Cell. Infect. Microbiol., 8.","DOI":"10.3389\/fcimb.2018.00239"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coviro.2012.02.011","article-title":"Degrees of maturity: The complex structure and biology of flaviviruses","volume":"2","author":"Pierson","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13567-021-00966-2","article-title":"Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics","volume":"52","author":"Zhang","year":"2021","journal-title":"Vet. Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Donaldson, M.K., Zanders, L.A., and Jose, J. (2025). Functional Roles and Host Interactions of Orthoflavivirus Non-Structural Proteins During Replication. Pathogens, 14.","DOI":"10.3390\/pathogens14020184"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"van den Elsen, K., Quek, J.P., and Luo, D. (2021). Molecular Insights into the Flavivirus Replication Complex. Viruses, 13.","DOI":"10.3390\/v13060956"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"10438","DOI":"10.1128\/JVI.00986-10","article-title":"The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex","volume":"84","author":"Gillespie","year":"2010","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/1743-422X-10-339","article-title":"Non-structural protein-1 is required for West Nile virus replication complex formation and viral RNA synthesis","volume":"10","author":"Youn","year":"2013","journal-title":"Virol. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/JVI.73.6.4611-4621.1999","article-title":"Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function","volume":"73","author":"Lindenbach","year":"1999","journal-title":"J. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ci, Y., Liu, Z.Y., Zhang, N.N., Niu, Y., Yang, Y., Xu, C., Yang, W., Qin, C.F., and Shi, L. (2020). Zika NS1-induced ER remodeling is essential for viral replication. J. Cell Biol., 219.","DOI":"10.1083\/jcb.201903062"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.coviro.2014.09.020","article-title":"Coupling of replication and assembly in flaviviruses","volume":"9","author":"Sirohi","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1128\/JVI.00037-07","article-title":"Structure of immature West Nile virus","volume":"81","author":"Zhang","year":"2007","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/emboj\/cdg270","article-title":"Structures of immature flavivirus particles","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/viro.1994.1013","article-title":"Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM","volume":"198","author":"Heinz","year":"1994","journal-title":"Virology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1126\/science.1153263","article-title":"The flavivirus precursor membrane-envelope protein complex: Structure and maturation","volume":"319","author":"Li","year":"2008","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1126\/science.1153264","article-title":"Structure of the immature dengue virus at low pH primes proteolytic maturation","volume":"319","author":"Yu","year":"2008","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1128\/JVI.01637-09","article-title":"Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion","volume":"83","author":"Yu","year":"2009","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41467-021-21505-9","article-title":"Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins","volume":"12","author":"Renner","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zheng, A., Umashankar, M., and Kielian, M. (2010). In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001157"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nsmb.2463","article-title":"Cryo-EM structure of the mature dengue virus at 3.5-A resolution","volume":"20","author":"Zhang","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1038\/s41467-022-31111-y","article-title":"Evolution and activation mechanism of the flavivirus class II membrane-fusion machinery","volume":"13","author":"Vaney","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Crampon, E., Covernton, E., Vaney, M.C., Dellarole, M., Sommer, S., Sharma, A., Haouz, A., England, P., Lepault, J., and Duquerroy, S. (2023). New insight into flavivirus maturation from structure\/function studies of the yellow fever virus envelope protein complex. mBio, 14.","DOI":"10.1128\/mbio.00706-23"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s44298-023-00004-2","article-title":"Zika virus M protein latches and locks the E protein from transitioning to an immature state after prM cleavage","volume":"1","author":"Majowicz","year":"2023","journal-title":"npj Viruses"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1038\/s41467-025-62750-6","article-title":"Irreversible furin cleavage site exposure renders immature tick-borne flaviviruses fully infectious","volume":"16","author":"Holoubek","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1038\/s41467-019-12677-6","article-title":"Oligomeric state of the ZIKV E protein defines protective immune responses","volume":"10","author":"Metz","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1099\/vir.0.031427-0","article-title":"prM-antibody renders immature West Nile virus infectious in vivo","volume":"92","author":"Colpitts","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/JVI.01805-15","article-title":"Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site","volume":"90","author":"Smith","year":"2016","journal-title":"J. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Dejnirattisai","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Shukla, R., Shanmugam, R.K., Ramasamy, V., Arora, U., Batra, G., Acklin, J.A., Krammer, F., Lim, J.K., Swaminathan, S., and Khanna, N. (2020). Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement. eBioMedicine, 54.","DOI":"10.1016\/j.ebiom.2020.102738"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virol.2012.07.011","article-title":"Mutations in the West Nile prM protein affect VLP and virion secretion in vitro","volume":"433","author":"Calvert","year":"2012","journal-title":"Virology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virusres.2016.12.003","article-title":"Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection","volume":"229","author":"Wang","year":"2017","journal-title":"Virus Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Pinto, P.B.A., Barros, T.A.C., Lima, L.M., Pacheco, A.R., Assis, M.L., Pereira, B.A.S., Goncalves, A.J.S., Azevedo, A.S., Neves-Ferreira, A.G.C., and Costa, S.M. (2022). Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2. Viruses, 14.","DOI":"10.3390\/v14071452"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Carpio, K.L., and Barrett, A.D.T. (2021). Flavivirus NS1 and Its Potential in Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9060622"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.1247749","article-title":"Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system","volume":"343","author":"Akey","year":"2014","journal-title":"Science"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.coviro.2023.101305","article-title":"Flavivirus nonstructural proteins and replication complexes as antiviral drug targets","volume":"59","author":"Chew","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s44298-024-00031-7","article-title":"The endoplasmic reticulum (ER): A crucial cellular hub in flavivirus infection and potential target site for antiviral interventions","volume":"2","author":"Verhaegen","year":"2024","journal-title":"npj Viruses"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e02861-18","DOI":"10.1128\/mBio.02861-18","article-title":"Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus","volume":"10","author":"Bailey","year":"2019","journal-title":"mBio"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Tien, S.M., Chang, P.C., Lai, Y.C., Chuang, Y.C., Tseng, C.K., Kao, Y.S., Huang, H.J., Hsiao, Y.P., Liu, Y.L., and Lin, H.H. (2022). Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010469"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/14760584.3.2.199","article-title":"Recent advancement in flavivirus vaccine development","volume":"3","author":"Chang","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e02494-19","DOI":"10.1128\/mBio.02494-19","article-title":"A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies","volume":"11","author":"Mishra","year":"2020","journal-title":"mBio"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-021-01392-9","article-title":"Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection","volume":"27","author":"Salje","year":"2021","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: Alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-018-0092-2","article-title":"A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice","volume":"3","author":"Kum","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"127489","DOI":"10.1016\/j.vaccine.2025.127489","article-title":"From controversy to confidence: Strengthening dengue vaccines safety reporting","volume":"62","author":"Thuy","year":"2025","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Shukla, R., Beesetti, H., Brown, J.A., Ahuja, R., Ramasamy, V., Shanmugam, R.K., Poddar, A., Batra, G., Krammer, F., and Lim, J.K. (2020). Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. eBioMedicine, 60.","DOI":"10.1016\/j.ebiom.2020.102991"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14760584.2025.2490295","article-title":"TAK-003: Development of a tetravalent dengue vaccine","volume":"24","author":"DeAntonio","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100604","DOI":"10.1016\/j.jvacx.2024.100604","article-title":"Current status of the development of dengue vaccines","volume":"22","author":"Lee","year":"2025","journal-title":"Vaccine X"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_145","first-page":"219","article-title":"Stability of yellow fever vaccine","volume":"87","author":"Monath","year":"1996","journal-title":"Dev. Biol. Stand."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1016\/j.vaccine.2011.07.054","article-title":"Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines","volume":"29","author":"Wiggan","year":"2011","journal-title":"Vaccine"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/cti.2016.72","article-title":"Dengue virus antibodies enhance Zika virus infection","volume":"5","author":"Paul","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Garg, H., Yeh, R., Watts, D.M., Mehmetoglu-Gurbuz, T., Resendes, R., Parsons, B., Gonzales, F., and Joshi, A. (2021). Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection. BMC Immunol., 22.","DOI":"10.1186\/s12865-020-00389-2"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Fan, Y.C., Chiu, H.C., Chen, L.K., Chang, G.J., and Chiou, S.S. (2015). Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Neglected Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004167"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-3527(03)61010-9","article-title":"Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines","volume":"61","author":"Eckels","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1473-3099(20)30085-2","article-title":"Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: A single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial","volume":"20","author":"Stephenson","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1016\/j.vaccine.2018.12.026","article-title":"An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults","volume":"37","author":"Woods","year":"2019","journal-title":"Vaccine"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Vorovitch, M.F., Tuchynskaya, K.K., Kruglov, Y.A., Peunkov, N.S., Mostipanova, G.F., Kholodilov, I.S., Ivanova, A.L., Fedina, M.P., Gmyl, L.V., and Morozkin, E.S. (2024). An Inactivated West Nile Virus Vaccine Candidate Based on the Lineage 2 Strain. Vaccines, 12.","DOI":"10.3390\/vaccines12121398"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1016\/j.vaccine.2024.03.071","article-title":"Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older","volume":"42","author":"Yonekawa","year":"2024","journal-title":"Vaccine"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"taab193","DOI":"10.1093\/jtm\/taab193","article-title":"Effectiveness of two doses of tick-borne encephalitis (TBE) vaccine","volume":"29","author":"Pugh","year":"2022","journal-title":"J. Travel. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: Results of two large phase 3 clinical studies","volume":"24","author":"Konior","year":"2006","journal-title":"Vaccine"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0264-410X(92)90003-3","article-title":"A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens","volume":"10","author":"Harabacz","year":"1992","journal-title":"Vaccine"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/INF.0000000000004034","article-title":"Effectiveness of Tick-borne Encephalitis Vaccines in Children, Latvia, 2018\u20132020","volume":"42","author":"Zavadska","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41541-022-00537-2","article-title":"Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults","volume":"7","author":"Friberg","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1016\/j.vaccine.2007.01.116","article-title":"Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up","volume":"25","author":"Kundi","year":"2007","journal-title":"Vaccine"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Wollner, C.J., and Richner, J.M. (2021). mRNA Vaccines against Flaviviruses. Vaccines, 9.","DOI":"10.3390\/vaccines9020148"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"101398","DOI":"10.1016\/j.omtm.2024.101398","article-title":"Research progress of mosquito-borne virus mRNA vaccines","volume":"33","author":"Sun","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e02482-20","DOI":"10.1128\/JVI.02482-20","article-title":"A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Uddin, M.N., and Roni, M.A. (2021). Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9091033"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Korzun, T., Moses, A.S., Diba, P., Sattler, A.L., Taratula, O.R., Sahay, G., Taratula, O., and Marks, D.L. (2023). From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics. Pharmaceuticals, 16.","DOI":"10.3390\/ph16081088"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"24842","DOI":"10.1021\/acsnano.4c05088","article-title":"Lipid Nanoparticles Elicit Reactogenicity and Sickness Behavior in Mice Via Toll-Like Receptor 4 and Myeloid Differentiation Protein 88 Axis","volume":"18","author":"Korzun","year":"2024","journal-title":"ACS Nano"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/npjvaccines.2016.21","article-title":"In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine","volume":"1","author":"Muthumani","year":"2016","journal-title":"npj Vaccines"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"Davis","year":"2001","journal-title":"J. Virol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41541-021-00339-y","article-title":"Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques","volume":"6","author":"McCracken","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.4049\/jimmunol.1401597","article-title":"CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice","volume":"193","author":"Zellweger","year":"2014","journal-title":"J. Immunol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","article-title":"A new generation of vaccines based on alphavirus self-amplifying RNA","volume":"44","author":"Vanrell","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e187405","DOI":"10.1172\/jci.insight.187405","article-title":"Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism","volume":"10","author":"Lu","year":"2025","journal-title":"JCI Insight"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"eaba5068","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: A double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","article-title":"Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: Pooled phase 1, 2, 3a and 3b randomized, controlled trials","volume":"15","author":"Ho","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Battisti, P., Ykema, M.R., Kasal, D.N., Jennewein, M.F., Beaver, S., Weight, A.E., Hanson, D., Singh, J., Bakken, J., and Cross, N. (2025). A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1569454"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Zhong, Z., Portela Catani, J.P., Mc Cafferty, S., Couck, L., Van Den Broeck, W., Gorle, N., Vandenbroucke, R.E., Devriendt, B., Ulbert, S., and Cnops, L. (2019). Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine. Vaccines, 7.","DOI":"10.3390\/vaccines7030096"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Chahal, J.S., Fang, T., Woodham, A.W., Khan, O.F., Ling, J., Anderson, D.G., and Ploegh, H.L. (2017). An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-00193-w"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J. Control Release"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41541-022-00549-y","article-title":"A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability","volume":"7","author":"Voigt","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"113900","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ymthe.2021.03.005","article-title":"RNA-based vaccines and innate immune activation: Not too hot and not too cold","volume":"29","author":"Frederickson","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.omtn.2022.11.024","article-title":"Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines","volume":"31","author":"Tregoning","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41541-022-00573-y","article-title":"Immune gene expression analysis indicates the potential of a self-amplifying COVID-19 mRNA vaccine","volume":"7","author":"Ong","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"101262","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","article-title":"Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency","volume":"43","author":"McGee","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e2402936","DOI":"10.1002\/advs.202402936","article-title":"A Novel Self-Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations","volume":"11","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Kim, B.J., Hosn, R.R., Remba, T.K., Dye, J., Mak, H.H., Jeong, J.Y., Cornwall-Brady, M., Abraham, W., Maiorino, L., and Melo, M.B. (2025). Targeted suppression of type 1 interferon signaling during RNA delivery enhances vaccine-elicited immunity. bioRxiv.","DOI":"10.1101\/2025.03.09.642244"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Asghar, N., Melik, W., Paulsen, K.M., Pedersen, B.N., Bo-Granquist, E.G., Vikse, R., Stuen, S., Andersson, S., Strid, A., and Andreassen, A.K. (2022). Transient Expression of Flavivirus Structural Proteins in Nicotiana benthamiana. Vaccines, 10.","DOI":"10.3390\/vaccines10101667"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1743-422X-8-333","article-title":"Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice","volume":"8","author":"Zhang","year":"2011","journal-title":"Virol. J."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12250-018-0030-5","article-title":"Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice","volume":"33","author":"Dai","year":"2018","journal-title":"Virol. Sin."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Hua, R.H., Li, Y.N., Chen, Z.S., Liu, L.K., Huo, H., Wang, X.L., Guo, L.P., Shen, N., Wang, J.F., and Bu, Z.G. (2014). Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate. BMC Biotechnol., 14.","DOI":"10.1186\/1472-6750-14-62"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1099\/0022-1317-78-8-1861","article-title":"Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles","volume":"78","author":"Sugrue","year":"1997","journal-title":"J. Gen. Virol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.tibtech.2019.03.013","article-title":"Production and Biomedical Application of Flavivirus-like Particles","volume":"37","author":"Krol","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol. J."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"e0232224","DOI":"10.1128\/jvi.02322-24","article-title":"Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage","volume":"99","author":"Abbo","year":"2025","journal-title":"J. Virol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e0023924","DOI":"10.1128\/jvi.00239-24","article-title":"A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates","volume":"98","author":"Thoresen","year":"2024","journal-title":"J. Virol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e00834-17","DOI":"10.1128\/JVI.00834-17","article-title":"Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus","volume":"91","author":"Garg","year":"2017","journal-title":"J. Virol."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Wang, P.G., Kudelko, M., Lo, J., Siu, L.Y., Kwok, K.T., Sachse, M., Nicholls, J.M., Bruzzone, R., Altmeyer, R.M., and Nal, B. (2009). Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008325"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e00556-18","DOI":"10.1128\/JVI.00556-18","article-title":"Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine","volume":"92","author":"Tsai","year":"2018","journal-title":"J. Virol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Vang, L., Morello, C.S., Mendy, J., Thompson, D., Manayani, D., Guenther, B., Julander, J., Sanford, D., Jain, A., and Patel, A. (2021). Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009195"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Gupta, R., Arora, K., Roy, S.S., Joseph, A., Rastogi, R., Arora, N.M., and Kundu, P.K. (2023). Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1123805"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J. Invertebr. Pathol."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Srivastava, V., Nand, K.N., Ahmad, A., and Kumar, R. (2023). Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery. Vaccines, 11.","DOI":"10.3390\/vaccines11020479"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Fan, Y.C., Chen, J.M., Chen, Y.Y., Hsu, W.L., Chang, G.J., and Chiou, S.S. (2024). Low-temperature culture enhances production of flavivirus virus-like particles in mammalian cells. Appl. Microbiol. Biotechnol., 108.","DOI":"10.1007\/s00253-024-13064-y"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4161\/hv.22218","article-title":"Plant-derived virus-like particles as vaccines","volume":"9","author":"Chen","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Salvo, M.A., Kingstad-Bakke, B., Salas-Quinchucua, C., Camacho, E., and Osorio, J.E. (2018). Zika virus like particles elicit protective antibodies in mice. PLoS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006210"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/CVI.05412-11","article-title":"Poly-gamma-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus","volume":"19","author":"Okamoto","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.virol.2021.07.004","article-title":"Isolation of a novel insect-specific flavivirus with immunomodulatory effects in vertebrate systems","volume":"562","author":"Auguste","year":"2021","journal-title":"Virology"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Elrefaey, A.M., Abdelnabi, R., Rosales Rosas, A.L., Wang, L., Basu, S., and Delang, L. (2020). Understanding the Mechanisms Underlying Host Restriction of Insect-Specific Viruses. Viruses, 12.","DOI":"10.3390\/v12090964"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2021.03.014","article-title":"Chimeric Zika viruses containing structural protein genes of insect-specific flaviviruses cannot replicate in vertebrate cells due to entry and post-translational restrictions","volume":"559","author":"Tangudu","year":"2021","journal-title":"Virology"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Harrison, J.J., Hobson-Peters, J., Bielefeldt-Ohmann, H., and Hall, R.A. (2021). Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses. Vaccines, 9.","DOI":"10.3390\/vaccines9111230"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Dawurung, J.S., Harrison, J.J., Modhiran, N., Hall, R.A., Hobson-Peters, J., and de Malmanche, H. (2025). Serum-Free Suspension Culture of the Aedes albopictus C6\/36 Cell Line for Chimeric Orthoflavivirus Vaccine Production. Viruses, 17.","DOI":"10.3390\/v17020250"},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Hall, R.A., Nguyen, W., Khromykh, A.A., and Suhrbier, A. (2025). Insect-specific virus platforms for arbovirus vaccine development. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1521104"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Porier, D.L., Wilson, S.N., Auguste, D.I., Leber, A., Coutermarsh-Ott, S., Allen, I.C., Caswell, C.C., Budnick, J.A., Bassaganya-Riera, J., and Hontecillas, R. (2021). Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9101142"},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Porier, D.L., Adam, A., Kang, L., Michalak, P., Tupik, J., Santos, M.A., Tanelus, M., Lopez, K., Auguste, D.I., and Lee, C. (2024). Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012566"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Vet, L.J., Setoh, Y.X., Amarilla, A.A., Habarugira, G., Suen, W.W., Newton, N.D., Harrison, J.J., Hobson-Peters, J., Hall, R.A., and Bielefeldt-Ohmann, H. (2020). Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus. Vaccines, 8.","DOI":"10.3390\/vaccines8020258"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Hazlewood, J.E., Tang, B., Yan, K., Rawle, D.J., Harrison, J.J., Hall, R.A., Hobson-Peters, J., and Suhrbier, A. (2022). The Chimeric Binjari-Zika Vaccine Provides Long-Term Protection against ZIKA Virus Challenge. Vaccines, 10.","DOI":"10.3390\/vaccines10010085"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/0091-6749(84)90183-0","article-title":"Human hypersensitivity to a sham vaccine prepared from mosquito-cell culture fluids","volume":"74","author":"Scott","year":"1984","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Carvalho, V.L., and Long, M.T. (2021). Perspectives on New Vaccines against Arboviruses Using Insect-Specific Viruses as Platforms. Vaccines, 9.","DOI":"10.3390\/vaccines9030263"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1073\/pnas.1304300110","article-title":"Dengue structure differs at the temperatures of its human and mosquito hosts","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 \u00b0C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J. Virol."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Gwon, Y.D., Zusinaite, E., Merits, A., Overby, A.K., and Evander, M. (2020). N-glycosylation in the Pre-Membrane Protein Is Essential for the Zika Virus Life Cycle. Viruses, 12.","DOI":"10.3390\/v12090925"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"eaax7888","DOI":"10.1126\/scitranslmed.aax7888","article-title":"A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus","volume":"11","author":"Harrison","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1128\/CVI.00070-07","article-title":"Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses","volume":"14","author":"Luo","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.chom.2019.10.001","article-title":"Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-\u03b1\u03b2R\u2212\/\u2212. Mice","volume":"26","author":"Larocca","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Bullard, B.L., Corder, B.N., Gorman, M.J., Diamond, M.S., and Weaver, E.A. (2018). Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-35755-z"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"Abbink","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"Sumida","year":"2004","journal-title":"J. Virol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J. Virol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"e160565","DOI":"10.1172\/JCI160565","article-title":"Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months","volume":"132","author":"Sobieszczyk","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jgm.837","article-title":"A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus","volume":"8","author":"Iglesias","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"de Wispelaere, M., Ricklin, M., Souque, P., Frenkiel, M.P., Paulous, S., Garcia-Nicolas, O., Summerfield, A., Charneau, P., and Despres, P. (2015). A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs. PLoS Neglected Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004081"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.celrep.2019.01.025","article-title":"Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses","volume":"26","author":"Cousin","year":"2019","journal-title":"Cell Rep."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Mahesh, S., Li, J., Travieso, T., Psaradelli, D., Negri, D., Klotman, M., Cara, A., and Blasi, M. (2023). Integrase Defective Lentiviral Vector Promoter Impacts Transgene Expression in Target Cells and Magnitude of Vector-Induced Immune Responses. Viruses, 15.","DOI":"10.3390\/v15112255"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Gallinaro, A., Borghi, M., Bona, R., Grasso, F., Calzoletti, L., Palladino, L., Cecchetti, S., Vescio, M.F., Macchia, D., and Morante, V. (2018). Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00171"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-022-00465-1","article-title":"Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers","volume":"7","author":"Gallinaro","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2020.01.013","article-title":"Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice","volume":"17","author":"Gallinaro","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Blasi, M., Negri, D., LaBranche, C., Alam, S.M., Baker, E.J., Brunner, E.C., Gladden, M.A., Michelini, Z., Vandergrift, N.A., and Wiehe, K.J. (2018). IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Commun. Biol., 1.","DOI":"10.1038\/s42003-018-0131-6"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ymthe.2020.05.016","article-title":"A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus","volume":"28","author":"Ku","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Coutant, F., Frenkiel, M.P., Despres, P., and Charneau, P. (2008). Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003973"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.03.008","article-title":"Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity","volume":"17","author":"Lin","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.ijpara.2009.05.005","article-title":"Functional role of 64P, the candidate transmission-blocking vaccine antigen from the tick, Rhipicephalus appendiculatus","volume":"39","author":"Havlikova","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Labuda, M., Trimnell, A.R., Lickova, M., Kazimirova, M., Davies, G.M., Lissina, O., Hails, R.S., and Nuttall, P.A. (2006). An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.0020027"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e00395-19","DOI":"10.1128\/JVI.00395-19","article-title":"Aedes aegypti NeSt1 Protein Enhances Zika Virus Pathogenesis by Activating Neutrophils","volume":"93","author":"Hastings","year":"2019","journal-title":"J. Virol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41564-019-0385-x","article-title":"Aedes aegypti AgBR1 antibodies modulate early Zika virus infection of mice","volume":"4","author":"Uraki","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.vaccine.2021.01.072","article-title":"AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41590-018-0063-9","article-title":"Salivary factor LTRIN from Aedes aegypti facilitates the transmission of Zika virus by interfering with the lymphotoxin-beta receptor","volume":"19","author":"Jin","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/vim.2012.0051","article-title":"Immunization with Culex tarsalis mosquito salivary gland extract modulates West Nile virus infection and disease in mice","volume":"26","author":"Reagan","year":"2013","journal-title":"Viral Immunol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/S0140-6736(20)31048-5","article-title":"Safety and immunogenicity of a mosquito saliva peptide-based vaccine: A randomised, placebo-controlled, double-blind, phase 1 trial","volume":"395","author":"Manning","year":"2020","journal-title":"Lancet"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s13071-016-1802-0","article-title":"Arbovirosis and potential transmission blocking vaccines","volume":"9","author":"Troupin","year":"2016","journal-title":"Parasites Vectors"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00005-014-0324-8","article-title":"Transmission-Blocking Vaccines: Focus on Anti-Vector Vaccines against Tick-Borne Diseases","volume":"63","author":"Neelakanta","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1021\/acs.biomac.4c01831","article-title":"Tetravalent Virus-like Particles Engineered To Display Envelope Domain IIIs of Four Dengue Serotypes in Silkworm as Vaccine Candidates","volume":"26","author":"Muthuraman","year":"2025","journal-title":"Biomacromolecules"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1021\/acs.biomac.5c00459","article-title":"Virus-Like Particle-Based Multiserotype Quartet Vaccine of Dengue Envelope Protein Domain III Elicited Potent Anti-Dengue Responses","volume":"26","author":"Boonyakida","year":"2025","journal-title":"Biomacromolecules"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41541-025-01179-w","article-title":"Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference","volume":"10","author":"Phan","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"eabg4084","DOI":"10.1126\/sciadv.abg4084","article-title":"Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies","volume":"7","author":"Kudlacek","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Garg, H., Mehmetoglu-Gurbuz, T., and Joshi, A. (2020). Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-61103-1"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"e01274-17","DOI":"10.1128\/JVI.01274-17","article-title":"Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge","volume":"92","author":"Erasmus","year":"2018","journal-title":"J. Virol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1016\/j.vaccine.2023.06.068","article-title":"Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice","volume":"41","author":"Carrera","year":"2023","journal-title":"Vaccine"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1016\/j.vaccine.2021.10.049","article-title":"Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives","volume":"39","author":"Palomares","year":"2021","journal-title":"Vaccine"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"e34927","DOI":"10.1016\/j.heliyon.2024.e34927","article-title":"Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview","volume":"10","author":"Henriquez","year":"2024","journal-title":"Heliyon"},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Rothen, D.A., Dutta, S.K., Krenger, P.S., Pardini, A., Vogt, A.S., Josi, R., Lieknina, I., Osterhaus, A., Mohsen, M.O., and Vogel, M. (2024). Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines. Vaccines, 12.","DOI":"10.3390\/vaccines12091053"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Saito, Y., Moi, M.L., Takeshita, N., Lim, C.K., Shiba, H., Hosono, K., Saijo, M., Kurane, I., and Takasaki, T. (2016). Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1873-8"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13567-014-0130-7","article-title":"Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals","volume":"45","author":"Prow","year":"2014","journal-title":"Vet. Res."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2018.01.075","article-title":"Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine","volume":"36","author":"Yun","year":"2018","journal-title":"Vaccine"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","article-title":"An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses","volume":"91","author":"Lobigs","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Wu, S.J., Ewing, D., Sundaram, A.K., Chen, H.W., Liang, Z., Cheng, Y., Jani, V., Sun, P., Gromowski, G.D., and De La Barrera, R.A. (2022). Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice. Microorganisms, 10.","DOI":"10.3390\/microorganisms10051034"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Eder","year":"2010","journal-title":"Vaccine"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"e00671-19","DOI":"10.1128\/mSphere.00671-19","article-title":"Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1","volume":"5","author":"Friberg","year":"2020","journal-title":"mSphere"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2008.02.009","article-title":"The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus","volume":"26","author":"Shrestha","year":"2008","journal-title":"Vaccine"},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Yang, L., Xiao, A., Wang, H., Zhang, X., Zhang, Y., Li, Y., Wei, Y., Liu, W., and Chen, C. (2022). A VLP-Based Vaccine Candidate Protects Mice against Japanese Encephalitis Virus Infection. Vaccines, 10.","DOI":"10.3390\/vaccines10020197"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1743-422X-7-146","article-title":"A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice","volume":"7","author":"Spohn","year":"2010","journal-title":"Virol. J."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/infdis\/jiad238","article-title":"A Chimeric Classical Insect-Specific Flavivirus Provides Complete Protection Against West Nile Virus Lethal Challenge in Mice","volume":"229","author":"Zhang","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41541-024-00903-2","article-title":"A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge","volume":"9","author":"Harrison","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","article-title":"Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans","volume":"10","author":"Kalimuddin","year":"2025","journal-title":"Nat. Microbiol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:21:49Z","timestamp":1767864109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":310,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["vaccines13101015"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13101015","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}